Delcath’s Percutaneous Hepatic Perfusion (PHP) technology allows physicians to deliver significantly higher doses of existing chemotherapy drugs to the liver without exposing each patient’s entire body to the anti-cancer drugs.
Diabetes Drug Wins Approval, Helps the Competition
The approval of Novo Nordisk’s diabetes drug Victoza has led to an unintended benefit for a competitor.
